Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,483,294
  • Shares Outstanding, K 99,706
  • Annual Sales, $ 2,355 M
  • Annual Income, $ 341,300 K
  • EBIT $ 550 M
  • EBITDA $ 551 M
  • 60-Month Beta 0.27
  • Price/Sales 6.22
  • Price/Cash Flow 43.47
  • Price/Book 4.88

Options Overview Details

View History
  • Implied Volatility 33.06% (-0.01%)
  • Historical Volatility 29.58%
  • IV Percentile 45%
  • IV Rank 22.92%
  • IV High 69.08% on 04/08/25
  • IV Low 22.35% on 08/29/25
  • Expected Move (DTE 18) 7.21 (5.02%)
  • Put/Call Vol Ratio 5.50
  • Today's Volume 13
  • Volume Avg (30-Day) 317
  • Put/Call OI Ratio 1.63
  • Today's Open Interest 8,387
  • Open Int (30-Day) 9,578
  • Expected Range 136.41 to 150.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.89
  • Number of Estimates 7
  • High Estimate 2.34
  • Low Estimate 1.65
  • Prior Year 1.00
  • Growth Rate Est. (year over year) +89.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.00 +2.13%
on 12/19/25
160.18 -10.09%
on 12/08/25
-8.15 (-5.36%)
since 11/28/25
3-Month
133.61 +7.78%
on 10/29/25
160.18 -10.09%
on 12/08/25
+3.74 (+2.67%)
since 09/29/25
52-Week
84.23 +70.97%
on 04/09/25
160.18 -10.09%
on 12/08/25
+4.57 (+3.28%)
since 12/27/24

Most Recent Stories

More News
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

SAN DIEGO , Dec. 22, 2025 /PRNewswire/ --  Neurocrine Biosciences, Inc.  (Nasdaq: NBIX) today announced that its Phase 3 KINECT ® -DCP study evaluating the efficacy, safety, and tolerability...

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology

Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences to Host R&D Day on December 16

SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00...

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic,...

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences to Present at Upcoming Investor Conferences

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational...

NBIX : 143.92 (-0.92%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth

NBIX : 143.92 (-0.92%)
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules

SAN DIEGO , Oct. 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT ® ...

NBIX : 143.92 (-0.92%)
Neurocrine (NBIX) Gets a Buy from Wells Fargo

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Neurocrine, with a price target of $180.00. The company’s shares closed yesterday at $137.35.Elevate Your Investing...

NBIX : 143.92 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 148.62
2nd Resistance Point 147.70
1st Resistance Point 146.48
Last Price 143.92
1st Support Level 144.34
2nd Support Level 143.43
3rd Support Level 142.21

See More

52-Week High 160.18
Last Price 143.92
Fibonacci 61.8% 131.17
Fibonacci 50% 122.21
Fibonacci 38.2% 113.24
52-Week Low 84.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar